Study: Daiichi Sankyo's anticoagulant outperforms standard treatment

Data on more than 8,000 patients with venous thromboembolism showed that those who received Daiichi Sankyo's anticoagulant drug edoxaban had fewer cases of bleeding than those who received warfarin. The drug also appeared to be safer than standard treatment and works well for patients with more severe conditions, researchers reported in the New England Journal of Medicine.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ